Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Scot C Remick

Showing results (71-80 of 93) with videos related to

Pageof 10
Sort By:
International Journal of Cancer|May 3, 2016
Factors influencing survival among Kenyan children diagnosed with endemic Burkitt lymphoma between 2003 and 2011: A historical cohort studyGeoffrey Buckle, Louise Maranda, Jodi Skiles, et al.
American Heart Journal|February 7, 2012
Management of cardiac toxicity in patients receiving vascular endothelial growth factor signaling pathway inhibitorsRichard M Steingart, George L Bakris, Helen X Chen, et al.
Oncotarget|June 4, 2016
MLLT11/AF1q boosts oncogenic STAT3 activity through Src-PDGFR tyrosine kinase signalingJino Park, Soojin Kim, Joongho Joh, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 4, 2008
A phase I study of 17-allylamino-17-demethoxygeldanamycin combined with paclitaxel in patients with advanced solid malignanciesSuresh S Ramalingam, Merrill J Egorin, Ramesh K Ramanathan, et al.
Journal of the National Cancer Institute|March 31, 2010
Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitorsMichael L Maitland, George L Bakris, Henry R Black, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 7, 2009
A vasculature-targeting regimen of preoperative docetaxel with or without bevacizumab for locally advanced breast cancer: impact on angiogenic biomarkersJoseph Baar, Paula Silverman, Janice Lyons, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 19, 2007
Dose-escalating and pharmacologic study of oxaliplatin in adult cancer patients with impaired hepatic function: a National Cancer Institute Organ Dysfunction Working Group studyTimothy W Synold, Chris H Takimoto, James H Doroshow, et al.
Thyroid : Official Journal of the American Thyroid Association|June 1, 2013
Randomized safety and efficacy study of fosbretabulin with paclitaxel/carboplatin against anaplastic thyroid carcinomaJulie A Sosa, Rossella Elisei, Barbara Jarzab, et al.
Thyroid : Official Journal of the American Thyroid Association|March 7, 2009
A phase II trial of fosbretabulin in advanced anaplastic thyroid carcinoma and correlation of baseline serum-soluble intracellular adhesion molecule-1 with outcomeColin J Mooney, Govardhanan Nagaiah, Pingfu Fu, et al.
The West Virginia Medical Journal|December 17, 2009
Building a statewide clinical trials network for cancer care in West VirginiaJame Abraham, James Keresztury, John Azar, et al.
Pageof 10

Showing results (71-80 of 93) with videos related to

Sort By:
Pageof 10
International Journal of Cancer|May 3, 2016
Factors influencing survival among Kenyan children diagnosed with endemic Burkitt lymphoma between 2003 and 2011: A historical cohort studyGeoffrey Buckle, Louise Maranda, Jodi Skiles, et al.
American Heart Journal|February 7, 2012
Management of cardiac toxicity in patients receiving vascular endothelial growth factor signaling pathway inhibitorsRichard M Steingart, George L Bakris, Helen X Chen, et al.
Oncotarget|June 4, 2016
MLLT11/AF1q boosts oncogenic STAT3 activity through Src-PDGFR tyrosine kinase signalingJino Park, Soojin Kim, Joongho Joh, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 4, 2008
A phase I study of 17-allylamino-17-demethoxygeldanamycin combined with paclitaxel in patients with advanced solid malignanciesSuresh S Ramalingam, Merrill J Egorin, Ramesh K Ramanathan, et al.
Journal of the National Cancer Institute|March 31, 2010
Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitorsMichael L Maitland, George L Bakris, Henry R Black, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 7, 2009
A vasculature-targeting regimen of preoperative docetaxel with or without bevacizumab for locally advanced breast cancer: impact on angiogenic biomarkersJoseph Baar, Paula Silverman, Janice Lyons, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 19, 2007
Dose-escalating and pharmacologic study of oxaliplatin in adult cancer patients with impaired hepatic function: a National Cancer Institute Organ Dysfunction Working Group studyTimothy W Synold, Chris H Takimoto, James H Doroshow, et al.
Thyroid : Official Journal of the American Thyroid Association|June 1, 2013
Randomized safety and efficacy study of fosbretabulin with paclitaxel/carboplatin against anaplastic thyroid carcinomaJulie A Sosa, Rossella Elisei, Barbara Jarzab, et al.
Thyroid : Official Journal of the American Thyroid Association|March 7, 2009
A phase II trial of fosbretabulin in advanced anaplastic thyroid carcinoma and correlation of baseline serum-soluble intracellular adhesion molecule-1 with outcomeColin J Mooney, Govardhanan Nagaiah, Pingfu Fu, et al.
The West Virginia Medical Journal|December 17, 2009
Building a statewide clinical trials network for cancer care in West VirginiaJame Abraham, James Keresztury, John Azar, et al.
Pageof 10